Isoprinosine

Inosine Pranobex, the active ingredient in Isoprinosine, is an immunomodulator presented as an oral formulation for oral use. It is used to treat viral infections such as herpes simplex and influenza, and to provide immunostimulation in certain immunodeficiency conditions.

GNH USA supplies Isoprinosine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies, clinics and research institutions worldwide.

Isoprinosine acts on viral replication pathways and on the host immune response, making it useful for several infectious and immunodeficiency conditions. - Herpes simplex infection: reduces lesion duration and viral shedding. - Influenza: alleviates symptoms and may shorten the course of illness. - Immunodeficiency states: enhances immune response and supports recovery.

Adverse reactions may occur with any dose of Isoprinosine.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hepatic enzyme elevation: possible liver function abnormalities. - Hematologic changes: including thrombocytopenia or leukopenia. - Stevens‑Johnson syndrome: rare severe skin reaction.

Before initiating therapy, consider the following safety measures. - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown; evaluate potential infant exposure. - Renal impairment: monitor renal function and adjust if necessary. - Hepatic impairment: use with caution and observe liver enzymes. - Concomitant immunosuppressants: may reduce immunostimulatory effect. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Isoprinosine may interact with other medicines; review the following.

Major Interactions (Avoid): - Live vaccines: may diminish vaccine efficacy; avoid concurrent administration. - Immunosuppressive agents: can counteract the drug’s immunostimulatory action.

Moderate Interactions (Monitor Closely): - Anticoagulants: possible increased bleeding risk. - Corticosteroids: may reduce immune response. - Antiretrovirals: potential pharmacodynamic interaction requiring monitoring.